Literature DB >> 35693390

Peripancreatic vascular involvement in patients with type 1 autoimmune pancreatitis.

Meizi Li1, Xiaoyin Bai1, Kai Xu2, Xi Wu1, Tao Guo1, Qingwei Jiang1, Qiang Wang1, Shengyu Zhang1, Yingyun Yang1, Yunlu Feng1, Aiming Yang1.   

Abstract

Background: Type 1 autoimmune pancreatitis (AIP) is the pancreatic manifestation of IgG4-related disease. However, this benign disease can result in the peripancreatic vascular involvement (PVI) on occasion, which increases the difficulty of diagnosis and treatment of this clinical entity as well as for differentiating it from pancreatic malignancies.
Methods: We retrospectively reviewed the information on demographics, clinical presentation, laboratory, imaging and endoscopic findings of 101 hospitalized patients with type 1 AIP treated in our department. All the patients were divided into non-PVI and PVI groups according to the first hospitalized medical data. Univariate and multivariate analyses were performed to analyse the potential predictive parameter(s) of PVI in AIP patients.
Results: Among the 101 type 1 AIP patients, 52 (51.5%) exhibited PVI, with a male/female ratio 5.5:1. Their average age was 58.37±8.68 years old. Univariate analysis revealed that the location of pancreatitis lesions, including the pancreatic tail (P=0.010), the presence of splenomegaly (P=0.001) and the white blood cell (WBC) number in peripheral blood (P=0.020), were significantly associated with PVI. The location of pancreatitis lesions, including the pancreatic tail (P=0.023), and the presence of splenomegaly (P=0.010) were found to be independent predictors of the development of PVI by a multivariable regression analysis. A total of 18 out of 25 patients in PVI group who underwent corticosteroid treatment and no less than 6 months radiological follow-up showed improvement in vascular lesions, and no case exhibited exacerbation of PVI lesions during follow-up. Of 36 patients in non-PVI group who were followed up for no less than 6 months, only one case exhibited PVI. Conclusions: This retrospective study demonstrated that type 1 AIP was associated with a high proportion of PVI. Pancreatic tail involvement and splenomegaly may predict the PVI in type 1 AIP. PVI lesions are reversible in a subset of patients. 2022 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Autoimmune pancreatitis (AIP); IgG4-related disease (IgG4-RD); corticosteroid treatment; peripancreatic vascular involvement (PVI); splenomegaly

Year:  2022        PMID: 35693390      PMCID: PMC9186208          DOI: 10.21037/hbsn-21-82

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   8.265


  15 in total

1.  Extrapancreatic lesions in autoimmune pancreatitis.

Authors:  Terumi Kamisawa; Naoto Egawa; Hitoshi Nakajima; Kouji Tsuruta; Atsutake Okamoto
Journal:  J Clin Gastroenterol       Date:  2005 Nov-Dec       Impact factor: 3.062

2.  Mechanism of immunoglobulin G4 Fab-arm exchange.

Authors:  Theo Rispens; Pleuni Ooijevaar-de Heer; Onno Bende; Rob C Aalberse
Journal:  J Am Chem Soc       Date:  2011-06-15       Impact factor: 15.419

Review 3.  Splenic involvement in rheumatic diseases.

Authors:  D Fishman; D A Isenberg
Journal:  Semin Arthritis Rheum       Date:  1997-12       Impact factor: 5.532

4.  IgG4-related disease: a cross-sectional study of 114 cases.

Authors:  Yoh Zen; Yasuni Nakanuma
Journal:  Am J Surg Pathol       Date:  2010-12       Impact factor: 6.394

5.  Reduction of splenic volume by steroid therapy in cases with autoimmune pancreatitis.

Authors:  Hiroyuki Matsubayashi; Katsuhiko Uesaka; Hideyuki Kanemoto; Takeshi Aramaki; Yoshihiro Nakaya; Naomi Kakushima; Hiroyuki Ono
Journal:  J Gastroenterol       Date:  2012-10-18       Impact factor: 7.527

6.  Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases.

Authors:  Kenji Notohara; Lawrence J Burgart; Dhiraj Yadav; Suresh Chari; Thomas C Smyrk
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

7.  Evaluation and management of autoimmune pancreatitis: experience at a large US center.

Authors:  Amit Raina; Dhiraj Yadav; Alyssa M Krasinskas; Kevin M McGrath; Asif Khalid; Michael Sanders; David C Whitcomb; Adam Slivka
Journal:  Am J Gastroenterol       Date:  2009-06-16       Impact factor: 10.864

8.  Dual-phase CT of autoimmune pancreatitis: a multireader study.

Authors:  Naoki Takahashi; Joel G Fletcher; Jeff L Fidler; David M Hough; Akira Kawashima; Suresh T Chari
Journal:  AJR Am J Roentgenol       Date:  2008-02       Impact factor: 3.959

9.  Lymphoplasmacytic sclerosing pancreatitis forming a localized mass: a variant form of autoimmune pancreatitis.

Authors:  Go Kobayashi; Naotaka Fujita; Yutaka Noda; Kei Ito; Jun Horaguchi; Osamu Takasawa; Takashi Obana; Kazunari Nakahara; Miwa Uzuki; Takashi Sawai
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

Review 10.  Gastric varices and splenic vein obstruction during steroid treatment for autoimmune pancreatitis: A case report and literature review.

Authors:  Lindsay A Juarez; Roop R Gupta; Gregory W Ruhnke
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.